Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Merck
Chinese Patent Office
Fish and Richardson
Express Scripts
US Department of Justice
Colorcon
Queensland Health
Mallinckrodt

Generated: September 22, 2018

DrugPatentWatch Database Preview

Hyaluronidase recombinant human - Generic Drug Details

« Back to Dashboard

What are the generic sources for hyaluronidase recombinant human and what is the scope of hyaluronidase recombinant human patent protection?

Hyaluronidase recombinant human is the generic ingredient in one branded drug marketed by Halozyme Therap and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for hyaluronidase recombinant human. One supplier is listed for this compound.

Pharmacology for hyaluronidase recombinant human
Ingredient-typeGlycoside Hydrolases
Drug ClassEndoglycosidase

US Patents and Regulatory Information for hyaluronidase recombinant human

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859-001 Dec 2, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for hyaluronidase recombinant human

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0822 Netherlands ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2015031 Lithuania ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
138 Luxembourg ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
2016000049 Germany ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
780 Luxembourg ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Merck
Chinese Patent Office
Fish and Richardson
Express Scripts
US Department of Justice
Colorcon
Queensland Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.